These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3160717)

  • 1. Improved high-performance liquid chromatographic determination of pefloxacin and its metabolite norfloxacin in human plasma and tissue.
    Montay G; Tassel JP
    J Chromatogr; 1985 Apr; 339(1):214-8. PubMed ID: 3160717
    [No Abstract]   [Full Text] [Related]  

  • 2. Determination of norfloxacin, a new nalidixic acid analog, in human serum and urine by high-performance liquid chromatography.
    Boppana VK; Swanson BN
    Antimicrob Agents Chemother; 1982 May; 21(5):808-10. PubMed ID: 6213199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-performance liquid chromatography of pefloxacin and its main active metabolites in biological fluids.
    Montay G; Blain Y; Roquet F; Le Hir A
    J Chromatogr; 1983 Feb; 272(2):359-65. PubMed ID: 6220023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prostatic concentrations of norfloxacin using HPLC].
    Bologna M; Cavicchio GC; Forchetti CM; Rucci A; Di Nicola G; Vaggi L
    G Ital Chemioter; 1984; 31(1-2):59-63. PubMed ID: 6236124
    [No Abstract]   [Full Text] [Related]  

  • 5. High-performance liquid chromatographic procedure for the quantitation of norfloxacin in urine, serum and tissues.
    Forchetti C; Flammini D; Carlucci G; Cavicchio G; Vaggi L; Bologna M
    J Chromatogr; 1984 Jul; 309(1):177-82. PubMed ID: 6237115
    [No Abstract]   [Full Text] [Related]  

  • 6. Bactericidal intraprostatic concentrations of norfloxacin.
    Bologna M; Vaggi L; Forchetti CM; Martini E
    Lancet; 1983 Jul; 2(8344):280. PubMed ID: 6135100
    [No Abstract]   [Full Text] [Related]  

  • 7. Determination of pefloxacin and its main active metabolite in human serum by high-performance liquid chromatography.
    Abanmi N; Zaghloul I; El Sayed N; Al-Khamis KI
    Ther Drug Monit; 1996 Apr; 18(2):158-63. PubMed ID: 8721279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pefloxacine: diffusion into bronchial mucus].
    Morel C; Vergnaud M; Langeard M; Benard Y
    Pathol Biol (Paris); 1984 Jun; 32(5 Pt 2):516-9. PubMed ID: 6589585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitation of norfloxacin, a new antibacterial agent in human plasma and urine by ion-pair reverse-phase chromatography.
    Pauliukonis LT; Musson DG; Bayne WF
    J Pharm Sci; 1984 Jan; 73(1):99-102. PubMed ID: 6229625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage.
    Eandi M; Viano I; Di Nola F; Leone L; Genazzani E
    Eur J Clin Microbiol; 1983 Jun; 2(3):253-9. PubMed ID: 6224683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans.
    Montay G; Goueffon Y; Roquet F
    Antimicrob Agents Chemother; 1984 Apr; 25(4):463-72. PubMed ID: 6587830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-dependent pharmacokinetic study of pefloxacin, a new antibacterial agent, in humans.
    Barre J; Houin G; Tillement JP
    J Pharm Sci; 1984 Oct; 73(10):1379-82. PubMed ID: 6594505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Penetration of pefloxacin in human heart valves.
    Brion N; Lessana A; Mosset F; Lefevre JJ; Montay G
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():89-92. PubMed ID: 3458701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioassay procedures for norfloxacin.
    Bland J; Edison A; Huber J
    Eur J Clin Microbiol; 1983 Jun; 2(3):249-52. PubMed ID: 6224682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetics and tissue penetration of norfloxacin.
    Adhami ZN; Wise R; Weston D; Crump B
    J Antimicrob Chemother; 1984 Jan; 13(1):87-92. PubMed ID: 6230344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concentrations of pefloxacin in plasma and tissue after administration as surgical prophylaxis.
    Jacoberger B; Ubeaud G; Freys G; Pottecher T; Jung L; Koffel JC
    Antimicrob Agents Chemother; 1998 Feb; 42(2):425-7. PubMed ID: 9527798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative in vitro antistaphylococcal effect of norfloxacin and pefloxacin on 312 hospital strains].
    Ronco E; Pilliot J
    Pathol Biol (Paris); 1985 May; 33(5):381-4. PubMed ID: 3162139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative activities in vitro of 4 quinolones (nalidixic acid, pefloxacin, norfloxacin, ofloxacin) on 13 bacterial species].
    Rahal K
    Arch Inst Pasteur Alger; 1992; 58():41-84. PubMed ID: 1309146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective decontamination of the digestive tract by norfloxacin. A preliminary report.
    Pecquet SS; Andremont AO; Tancrède CH
    Prog Clin Biol Res; 1985; 181():255-8. PubMed ID: 3161086
    [No Abstract]   [Full Text] [Related]  

  • 20. In vitro activity of pefloxacin compared with five other quinolones on nalidixic acid-resistant proteae species.
    Piccolomini R; Cellini L; Allocati N; Di Girolamo A; Selan L; Scazzocchio F
    Chemioterapia; 1988 Oct; 7(5):287-91. PubMed ID: 3224396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.